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Primary biliary cirrhosis following lactobacillus vaccination
for recurrent vaginitisq
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1Institute of Liver Studies, King’s College, London School of Medicine at King’s College Hospital, London, United Kingdom
2Department of Medicine II-Grosshadern, University of Munich, Germany
3Department of Gastroenterology and Hepatology, AMC, University of Amsterdam, G4-213, Meibergdreef 9,
NL-1105 AZ Amsterdam, The NetherlandsBackground/Aims:Antimitochondrial antibodies directed against the E2 subunit of the pyruvate dehydrogenase com-
plex, PDC-E2, and other mitochondrial 2-oxoacid dehydrogenases (AMA-M2) are the hallmark for diagnosis of primary
biliary cirrhosis (PBC). AMA-M2 formation as an early step in the pathogenesis of PBC has recently been assumed to be
triggered by bacterial mimics of the E2 subunit and certain reactant xenobiotics. We report a case of symptomatic PBC
diagnosed after sequential immunization with a lactobacillus vaccine for recurrent vaginitis over years.
Methods: Serum AMA-M2 speciﬁcity of the patient was evaluated by indirect immunoﬂuorescence, immunoblotting and
ELISA. Serum antibody responses against pyruvate dehydrogenase complex-E2 subunit (PDC-E2212–226), the major PBC-
speciﬁc mitochondrial autoepitope, and microbial mimics revealed cross-reactivity with beta-galactosidase of Lactobacillus
delbrueckii (LACDE BGAL266–280) which shows a high local homology with that of Lactobacillus species administered via
the vaccine. The relative aﬃnity of antibody reactivity to LACDE BGAL266–280 was signiﬁcantly higher than that against
human PDC-E2212–226.
Conclusions:We conclude that lactobacillus vaccination therapy may be another culprit for the development of PBC in
genetically susceptible women.
 2008 Published by Elsevier B.V. on behalf of the European Association for the Study of the Liver.
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Primary biliary cirrhosis (PBC) is a chronic cholestatic
liver disease characterized by destruction of small intra-
hepatic bile ducts and subsequent development of liver
ﬁbrosis and cirrhosis predominantly in middle-aged0168-8278/$34.00  2008 Published by Elsevier B.V. on behalf of the Europ
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 These authors contributed equally to the manuscript.women [1]. Fatigue and pruritus are the most frequent
symptoms which may aﬀect up to 80% of patients [2,3].
PBC is regarded as an organ-speciﬁc autoimmune dis-
ease based on the presence of lymphoid inﬁltration in
the portal tracts and of high titers of speciﬁc antibodies
directed against the E2 subunit of pyruvate dehydroge-
nase complex (PDC-E2) or related mitochondrial 2-oxo-
acid dehydrogenase complexes (AMA-M2) [4,5]. The
induction of AMA-M2 formation may be multifactorial
[6]. Modiﬁcation of mitochondrial or bacterial proteins
after exposure to reactant xenobiotics such as the
cosmetic component, 2-nonynoic acid [7,8] or hazardous
aromatic hydrocarbons such as benzene [9] as well as
exposure to bacterial proteins with a high degree of
sequence homology with the human mitochondrial 2-
oxoacid dehydrogenase complexes like those ofean Association for the Study of the Liver.
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delbrueckii [11] might induce loss of tolerance to human
mitochondrial proteins in genetically susceptible individ-
uals. Aberrant expression of PDC-E2-like proteins possi-
bly derived from phagocytosed apoptotic biliary
epithelial cells [12] at the luminal surface of cholangio-
cytes [6] may contribute to an immune response leading
to ﬂorid cholangitis and bile duct destruction in PBC
[13].
Here, we report a case of primary biliary cirrhosis
diagnosed after immunization with a lactobacillus vac-
cine for years. The laboratory work-up was aimed to
investigate the ﬁne speciﬁcity of antibody responses
against pyruvate dehydrogenase complex-E2 subunit
(PDC-E2212–226), the major PBC-speciﬁc mitochondrial
autoepitope and its microbial mimics in this female
patient vaccinated annually for 8 years with Lactobacil-
lus antigens.
1.1. Case report
A 39-year-old previously healthy woman was referred
to our outpatient clinic in July 2005 with a 3-month his-
tory of fatigue, generalized severe pruritus and pruritus-
associated sleep disturbance. She and her family had no
history of liver disease or other serious disorders. She
worked as a banker and reported no regular intake of
drugs or herbs. She was a non-smoker and was neither
passively exposed to smoke nor to chemical toxins.
She had no children and had not used hormones in
the past [14]. Her gynaecologist had administered intra-
muscular lactobacillus vaccine [GynatrenR, >7  109
Lactobacilli of eight strains, L. rhamnosus (3), L. vaginalis
(3), L. fermentum (1), L. salivarius (1)] twice within sev-
eral weeks in the ﬁrst year and at one-year intervals for 8
years as an immunization therapy for prevention of
recurrent vaginitis [15]; serum liver tests or serum sam-
ples of the patient from that time were not available.
The patient’s physical examination was unremarkable.
Laboratory investigations showed elevated levels of
total serum bilirubin (1.3 mg/dL; normal (N) < 1.0 mg/
dL), alkaline phosphatase (363 IU/L; N < 135), c-glut-
amyltransferase (244 IU/L; N < 38), serum aspartateTable 1
Clinical symptoms and biochemical markers of the PBC patient during
UDCA + budesonide thereafter
Before treatment After 3 weeks (UDCA)
Pruritus (0–10) 8–9 3
Fatigue (0–+++) +++ +
Bilirubin (xN) 1.2 1.3
Alkaline Phosphatase (xN) 6.3 2.7
c-GT (xN) 15.4 6.4
ALT (xN) 5.5 4.5
AST (xN) 3.9 2.8
N = upper limit of normal.aminotransferase (92 IU/L; N < 33) and serum alanine
aminotransferase (158 IU/L; N < 35). Antimitochondri-
al antibody (AMA, 1:5120) and AMA-M2 were strongly
positive, and serum IgG (17.2 g/L; N 7.0–16.0) and IgM
(4.4 g/L; N 0.4–2.3) were elevated. Serological tests for
hepatitis A, B and C and antinuclear (ANA), anti-
smooth muscle (ASMA), and soluble liver antigen
(SLA) antibodies were negative. A liver biopsy revealed
portal and periportal lymphocellular inﬁltration with
signs of bile duct injury, ductopenia, moderate interface
hepatitis and portoseptal ﬁbrosis, compatible with stage
2–3 PBC. The diagnosis of a PBC–AIH overlap syn-
drome was considered unlikely (AIH score < 10)[16].
Therapy with ursodeoxycholic acid at 1000 mg/day
(15 mg/kg/d) was initiated, and budesonide at
2  3 mg/d was added after 9 months when serum liver
tests had only partially improved. The patient reported a
rapid improvement of pruritus and fatigue within weeks.
After 9–24 months, the patient reported general well-
being. Mild pruritus (<3/10) was observed only occa-
sionally. Fatigue and serum liver tests had markedly
improved (Table 1) whereas serum AMA titers remained
unchanged (1:3840 after 24 months, AMA-M2 positive).
The patient agreed to perform additional studies and her
serum samples were sent for further testing to the labo-
ratory of Liver Immunopathology, King’s College
London.2. Methods
2.1. Characterization of the patient’s AMA
2.1.1. Indirect immunoﬂuorescence (IIFL)
Two serum samples from the patient taken after more
than 6 months of ursodeoxycholic acid treatment were
tested for conventional autoantibodies by indirect
immunoﬂuorescence (IIFL) on 5 lm frozen sections of
a composite substrate containing rat liver, kidney and
stomach using as revealing reagent an antitotal human
IgG-ﬂuorescein isothiocyanate conjugate (Dako Ltd.,
High Wycombe, Bucks, UK) at a starting dilution of
1/40 [17]. Positive sera were titrated to extinction bytreatment with UDCA for 9 months and combined treatment with
After 9 months (UDCA) After 24 months (budesonide + UDCA)
0–3 0
(+) (+)
1.0 0.7
2.7 1.9
5.9 6.6
2.7 1.9
1.8 1.3
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pendent observer (Dr. E.T. Davies, Department of
Immunology, King’s College Hospital) using an Olym-
pus BX40 (Olympus Optical, London, UK) ﬂuorescence
microscope.
2.2. Antimitochondrial antibody reactivity by
immunoblotting
Antimitochondrial antibody speciﬁcity was further
evaluated by immunoblotting using strips pre-coated
with electrophoretically separated human liver mito-
chondrial subfractions [18,19]. Strips were incubated
for 30 min with individual serum samples at a dilution
of 1/200 and after three 5-min washings, they were
incubated for 1 h with an HRP-conjugated rabbit anti-
total human IgG (Dako Ltd., High Wycombe, Bucks,
UK), or HRP-conjugated murine antihuman IgG sub-
class-speciﬁc antisera (IgG1:clone JDC-1; IgG2:31-7-4;
IgG3:HP6050; IgG4:HP6025, Southern Biotechnology
Associates, Inc., Birmingham, AL, USA) diluted in
2% bovine serum albumin (BSA) in phosphate-buﬀered
saline (PBS) as revealing reagents [11,18,19]. After
washing, the blots were developed with diamino-benzi-
dine at 0.25 mg/ml in PBS with 0.1% H2O2 as sub-
strate. A reference strip from the same lot with
immunoﬁxed bands of known mitochondrial autoanti-
gens was used for comparative interpretation of the
results.
2.3. Autoantibody testing by ELISA
AMA-M2 autoantibody speciﬁcity was also analysed
by ELISA using as antigenic preparations puriﬁed M2
antigen from bovine heart mitochondria (Euroimmun).
Antibody reactivity against the major mitochondrial
autoantigens, namely the E2 subunits of the pyruvate
dehydrogenase complex (PDC), the branched chain oxo-
acid dehydrogenase complex (BCOADC) and the oxo-
glutarate dehydrogenase complex (OGDC) has been
further evaluated using a triple hybrid (-3) [20], express-
ing the immunodominant human PDC-E2, BCOADC-
E2 and OGDC-E2 regions (INOVA, San Diego, CA,
USA).
2.4. Amino acid similarities
The beta-galactosidase of Lactobacillus delbrueckii
(LACDE BGAL266–280) was recently identiﬁed as a tar-
get of immunological cross-reactivity in patients with
PBC due to its eight amino acids in a row (seven identi-
ties) similarity with the major human PDC-E2212–226
mitochondrial autoepitope [11]. The corresponding
BGAL of Lactobacillus salivarius is highly homologous
to LACDE BGAL266–280 (local homology 89%) and is
contained in the vaccine.2.5. Peptide synthesis
Two 15-mer biotinylated peptides containing the key
sequences of beta- galactosidase (lactase) of Lactobacil-
lus delbrueckii, subsp. bulgaricus (BGAL266–280 LACDE)
(RDSEGDLVAEKLGPI) and human PDC-E2212–226
(KLSEGDLLAEIETDK) and an irrelevant 15 aa con-
trol peptide (YVNQSLRPTPLEISV) [19,21,22] of com-
parable hydrophobicity were constructed using Fmoc
chemistry (Mimotopes Ltd., Clayton, Australia) [23].
The identity of each puriﬁed peptide was conﬁrmed by
mass spectrometry.
2.6. ELISA
Antibody binding to the peptides (5 lg/ml) was deter-
mined by ELISA (serum dilution 1/200) [19,21,22,24].
For detection of IgG class and IgG subclasses antibody
reactivity, an HRP-conjugated rabbit antitotal human
IgG, or antihuman IgG subclasses (see above) were
used. Reaction for a given peptide was considered posi-
tive when optical density (OD)test/ODcontrol/peptideP 2,
this cut-oﬀ representing mean + 5 SD of 135 readings
using serum (tested in triplicate) from 15 healthy sub-
jects against the mimicking peptides [19,21,22,24,25].
2.7. Inhibition studies
Competition ELISAs were performed to test for
cross-reactivity to LACDE BGAL266–280 and human
PDC-E2212–226, measuring residual anti-LACDE
BGAL266–280 or anti-PDC-E2212–226 reactivity, after
pre-incubation with LACDE BGAL266–280, PDC-
E2212–226, puriﬁed PDC antigen, control peptide and
control antigen (CYP2D6, Euroimmun), respectively,
as liquid phase competitors, as previously described
[11,19,21,22,24–27].
2.8. Determination of antipeptide antibody aﬃnity
The relative aﬃnity of antipeptide antibody binding
to LACDE BGAL266–280 and human PDC-E2212–226
was measured, as previously described [11,19,24,28]
using as chaotropic agent increasing concentrations (1–
8 M) of urea. The relative aﬃnity index (rAI), deﬁned
as the concentration of urea that elutes 50% of the anti-
body reactivity, for each of the two mimicking peptides
was extrapolated.
2.9. Inhibition of PDC enzymatic activity
The enzymatic inhibitory activity of the PBC serum
sample reactive to LACDE BGAL266–280/human PDC-
E2212–226 was measured as previously described [11,29]
before and after incubation of the serum with individual
human PDC-E2212–226 or LACDE BGAL266–280 pep-
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heart PDC (Sigma Aldrich, Dorset, UK). The enzymatic
activity was measured spectrophotometrically at 405 nm
as the formation of thio-NADH from thio-NAD
(Sigma) in the presence of the substrate pyruvate, and
the cofactors cocarboxylase (Sigma) and coenzyme A
(Sigma). Absorbance was read immediately and then
at minute intervals for 10 min. The rate of change in
absorbance was calculated, and the percent inhibition
was obtained using the standard reaction rate in wells
to which PBS (pH 7.4) was added instead of serum.
The PBC serum (1/10,000) was tested before and after
pre-incubation with each peptide. Tests were done in
triplicate and expressed with the following formula:
(mean percentage inhibition of the sample after pre-
incubation/mean percentage inhibition of the sample
before pre-incubation)  100. Repeat experiments gave
variations <10%.
2.10. Apoptosis studies
2.10.1. IgG puriﬁcation
IgG was puriﬁed from serum of the index patient
(IP), three normal controls (C1–C3), three AMA posi-
tive PBC patients (PBC1–PBC3) and two patients with
primary sclerosing cholangitis (PSC1–PSC2) using the
Melon Gel IgG puriﬁcation System (Pierce Biotechnol-
ogy, Rockford, IL, USA). Brieﬂy, 500 ll of melon gel
IgG was added to the column, centrifuged (4000g) and
washed twice with 300 ll of puriﬁcation buﬀer. Fifty
microliters of individual sera diluted 1/10 in melon gel
puriﬁcation buﬀer were added to the column, and incu-
bated for 5 min at room temperature with end-over-end
mixing. After removal of bottom cap from the column,
loosen top cap and re-inserting spin column in the col-
lection tube, followed by centrifugation for 1 min, the
puriﬁed antibody was collected and stored at 20 C.
2.11. H-69 cell culture
The immortalized human intrahepatic biliary epithelial
cell lineH-69was kindly provided byDr.D. Jeﬀerson, Bos-
ton. It was grown in DMEM/Ham’s F12medium (3:1, pH
7.4, 37 C, 5% CO2) containing 10% fetal calf serum,
100 U/mL penicillin, 100 lg/mL streptomycin (all from
PAA; Pasching, Austria), 1.8  104 mol/L adenine,
5 lg/mL insulin, 5 lg/mL transferrin, 2  109 mol/L tri-
iodthyronine, 1.1  106 mol/L hydrocortisone,
1.6  106 mol/L epidermal growth factor (all from Sigma
Chemical; St. Louis, MO, USA), and 5.5  106 mol/L
epinephrine (Jenapharm; Jena, Germany).
2.12. Caspase assays
Apoptosis was evaluated by measuring activation of
the eﬀector caspases 3/7 in subconﬂuent H-69 cells incu-bated with puriﬁed IgG (1 mg/ml) from both patients
and controls for 48 h. Etoposide (30 lmol/L) was used
as a positive control. Activity assays were performed
using a caspase 3/7 assay kit (Promega; Madison, WI,
USA).
2.13. Quantitative RT-PCR
Total RNA was isolated using the NucleoSpin RNA II
kit (Machery–Nagel, Du¨ren, Germany). Two micrograms
of total RNA were transcribed into cDNA by incubation
with 200–500 ng oligo-d(T)12–18 primer and 1 ll 10 mM
dNTP-mix in a volume of 13 ll for 5 min at 65 C. After
cooling on ice, 4 ll of 5 First-Strand-buﬀer, 1 ll 0.1 M
DTT, 1 ll RNase OUT and 1 ll Superscript III (Invitro-
gen, Karlsruhe, Germany) were added and incubated for
1 h at 50 C. Enzymes and RNA were degraded by heat-
ing for 15 min at 70 C and incubation with 1 ll RNase H
(Invitrogen) for 20 min at 37 C. For quantitative RT-
PCR, the PCR cycler Rotor Gene RG-3000 (Corbett
Research, Mortlake, Australia) and the QuantiTect
SYBR Green PCR-Kit (Qiagen, Hilden, Germany) were
applied. Quantiﬁcation was done using GAPDH as
endogenous control. Primer sequences: GAPDH forward
50-ACCACAGTCCATGCCATCAC-30 and reverse 50-T
CCACCACCCTGTTGCTGTA-30; human polymeric Ig
receptor (pIgR) forward 50-CCACCGTGGAGAT
CAAGATT-30 and reverse 50-CAGCCCGTGTTATTC
CACTT-3; and human neonatal Fc receptor (FcRn) for-
ward 50-GGCTCCTGCTCTTTCTCCTT-30 and reverse
50-TCTCCCAATACCAGGACACC-30.
2.14. Statistical analysis
Results are presented as means ± SD or percentages
(%). Data were analysed using Student’s t-test, Mann–
Whitney U test, chi-square (v2) test and the Fisher’s
exact test as appropriate. A two-tailed p value < 0.05
was considered signiﬁcant. Statistical analyses were per-
formed using SPSS (SPSS Inc., Chicago, IL, USA) sta-
tistical package.3. Results
AMA at a titer of 1/640 were detected in the serum of
thisPBCpatient aftermore than6months ofmedical treat-
ment. The sample was also positive using the -3 (PDC-E2,
BCOADC-E2 and OGDC-E2) triple hybrid (78 RU/ml,
cut-oﬀ: 20 RU/ml) by ELISA. The serum immunoﬁxed
major mitochondrial antigens including the 74 kDa
PDC-E2, the 51 kDa BCOADC-E2 and OGDC-E2
and to a lesser extent the 55 kDa PDC-E3 binding protein
(E3BP) and the 45 kDa PDC-E1a by immunoblotting.
IgG subclass distribution of AMA showed an IgG3
predominance for PDC-E2 (Fig. 1). Serum was reactive
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Fig. 1. IgG subclass distribution of AMA in serum of a PBC patient with
a history of Lactobacillus vaccination. Triplicate determination by
Western blotting revealed an IgG3 predominance for PDC-E2. For
details, see Sections 2 and 3.
0
3
6
PDC-E2212-226 BGAL266-280 LACDE
*
R
el
at
iv
e 
an
tib
od
y 
af
fin
ity
 (m
ol/
L)
Fig. 3. Relative antibody aﬃnity to Lactobacillus LACDE BGAL266–280
was signiﬁcantly higher than that against human PDC-E2212–226 in serum
of a PBC patient with a history of Lactobacillus vaccination. Relative
antibody aﬃnity was estimated as the concentration (mol/L) of the
chaotropic agent (urea) that elutes 50% of the peptide antibody
reactivity. For details, see Sections 2 and 3. *p < 0.05, two-sided
Student’s t-test.
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test/peptide/ODcontrol/peptide =
3.2) and with BGAL266–280 LACDE (7.5). Antibody
reactivity to human PDC-E2212–226 and BGAL266–280
LACDE belonged to the IgG3 subclass.
3.1. Inhibition studies
Competition ELISA experiments showed that human
PDC-E2212–226/BGAL266–280 LACDE reactivity was
cross-reactive. Preincubation with relevant and control
peptide/antigen revealed that IgG3 subclass antibody
binding to human PDC-E2212–226 was inhibited by
72% after preincubation with human PDC-E2212–226;
by 78% after preincubation with puriﬁed PDC antigen;
and by 73% after preincubation with LACDE
BGAL266–280. Insigniﬁcant inhibition was observed after
preincubation with irrelevant control peptide and antigen
(Fig. 2). Antibody binding to LACDE BGAL266–280PDC-E2 peptide
PDC antigen
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Control peptide
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Fig. 2. Binding to human PDC-E2212–226 of IgG3 subclass antibody from
serum of a PBC patient with a history of Lactobacillus vaccination was
inhibited after preincubation with relevant antigens. Inhibition was
determined by competition ELISA. For details, see Sections 2 and 3.was also signiﬁcantly inhibited by 78%, 71%, and 68%
after preincubation with LACDE BGAL266–280, PDC-
E2212–226, and PDC antigen, respectively.
3.2. Aﬃnity of antibody reactivity
The relative aﬃnity of antibody reactivity to LACDE
BGAL266–280 was signiﬁcantly higher than that against
human PDC-E2212–226 (Fig. 3). Inhibition of PDC enzy-
matic activity was 100% using the serum reactive to
LACDE BGAL266–280/human PDC-E2212–226 (1/1000
dilution). After preincubation with LACDE BGAL266–280,
this was reduced by 59%; after preincubation with
human PDC-E2212–226 it was reduced by 34%.
3.3. Apoptosis studies
In an immortalized human cholangiocyte cell line, H-
69, the human IgG neonatal Fc receptor (FcRn) and the
human IgA polymeric Ig receptor (pIgR) were expressed
as documented by quantitative RT-PCR (data not
shown). Incubation of human cholangiocytes for 48 h
with etoposide (positive control) induced a 5.5-fold acti-
vation of caspase 3/7 (Fig. 4) in comparison to control
cells incubated with the carrier only. Neither puriﬁed
IgG (1 mg/ml) of the index patient nor puriﬁed IgG of
three PBC patients, two PSC patients and three healthy
controls did aﬀect the rate of apoptosis in human cho-
langiocytes when compared to control cells (Fig. 4).
These data indicate that puriﬁed PBC IgG did not trig-
ger apoptosis in a human cholangiocyte cell line.4. Discussion
We present the case of a woman with an 8-year his-
tory of lactobacillus vaccination for recurrent vaginitis
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Fig. 4. Puriﬁed IgG of patients with PBC, PSC and healthy controls did not induce apoptosis in immortalized human cholangiocytes. H-69 cells were
incubated with puriﬁed immunoglobulin (Ig)G (1 mg/ml) from both patients (index patient, IP; three AMA positive control PBC patients, PBC 1–3; two
patients with primary sclerosing cholangitis, PSC 1–2) and controls (C 1–3) for 48 h. Etoposide (30  106 mol/L) was used as a positive control.
Apoptosis was quantiﬁed by measuring caspase 3/7 activity. For details, see Sections 2 and 3.
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histological features of primary biliary cirrhosis. In view
of known immunological cross-reactivity between a lac-
tobacillus sequence and the major autoepitope of antim-
itochondrial antibody [11] we characterized
autoreactivity and possible cross-reactivity [11,18,19,
21,22,24–27,30] in this patient ﬁnding that her serum
contains a high-titer AMA, which belongs mainly to
IgG3 subclass and targets the immunodominant PDC-
E2212–226 autoepitope. This serum also reacts with the
Lactobacillus delbrueckii subs. bulgaricus self-mimicking
BGAL266–280 sequence. The antibody shows the same
IgG subclass restriction and is indeed cross-reactive:
binding to the lactobacillus mimic is inhibited by the lac-
tobacillus and mitochondrial peptides but, importantly,
also by the full-length PDC-E2 autoantigen implying
that the cross-reactive microbial/self peptide recognition
involves the naturally occurring autoantigen. The ﬁnd-
ing that the relative aﬃnity of antibody binding to LAC-
DE BGAL266–280 is greater than that against human
PDC-E2212–226 (Fig. 3) suggests that antimicrobial reac-
tivity may have preceded that to the self mimic [11].
Lastly, the ability of the cross-reactive antibody to inhi-
bit PDC’s enzymatic activity emphasizes its biological
signiﬁcance [11,25].
Of the Lactobacilli strains contained in the vaccine,
the BGAL sequences deposited are only few. However,
that of L. salivarius is highly homologous (89% local
aa similarity) to that of Lactobacillus delbrueckii subs.
bulgaricus used as an antigenic target in the present
experiments in view of its previous characterization in
terms of immunological cross-reactivity with the mito-
chondrial autoepitope and its high speciﬁcity for pri-
mary biliary cirrhosis [11].
Incubation of human cholangiocytes with puriﬁed
IgG from the index patient and healthy and disease con-
trols revealed no detectable induction of apoptosis
although expression of the IgG neonatal Fc receptor,FcRn, was shown by quantitative RT-PCR. Thus,
PBC IgG-AMA apparently did not cause apoptosis in
contrast to ﬁndings reported previously by Matsumura
et al. [31] who showed caspase activation by PBC IgA,
but not control IgA in MDCK cells transfected with
pIgR. The diﬀerence may be explained in various ways:
(i) IgA-AMA may be more appropriate than IgG-AMA
to induce apoptosis in human cholangiocytes; (ii) the
FcRn expressed in H-69 cells was not functional; (iii)
the experimental conditions were inappropriate to
induce apoptosis mediated by IgG-AMA. The observa-
tion that also puriﬁed IgG from disease controls did not
cause apoptosis under the conditions chosen, rather sup-
ports these assumptions. Thus, the pathophysiological
relevance of IgG-AMA remains unclear.
The patient and her physicians were unable to pro-
vide informations about serum liver tests before start
of lactobacillus vaccination. In addition, no serum sam-
ples were available for AMA testing from the time
before start of lactobacillus vaccination. This weakens
the assumption that lactobacillus vaccination has caused
AMA formation and development of PBC in the patient
presented here considering that AMA formation may
preceed development of biochemical and clinical signs
of PBC by years [6]. Still, the greater aﬃnity of antibody
binding to LACDE BGAL266–280 than that against
human PDC-E2212–226 remains intriguing.
In our symptomatic patient, UDCA monotherapy
has improved symptoms and serum liver tests (Table
1). A complete biochemical response had been unlikely
considering that the patient presented with serum biliru-
bin >1 mg/dl and at least moderate periportal/periseptal
lymphocyte interface hepatitis and portoseptal ﬁbrosis,
risk markers for a progressive course of PBC[32]. Eval-
uation of combined treatment with UDCA and budeso-
nide has been suggested for this particular subgroup of
patients for further evaluation within a controlled clini-
cal trial[33]. Combined treatment with UDCA and
472 D. Bogdanos et al. / Journal of Hepatology 49 (2008) 466–473budenoside at a moderate dose led to further improve-
ment of biochemical parameters. Lack of signiﬁcant
changes in serum AMA titers made it unlikely that ces-
sation of vaccination therapy during therapy has con-
tributed to the beneﬁcial eﬀect of medical treatment.
In conclusion, we report on a female patient in whom
lactobacillus vaccination therapy for the prevention of
recurrent vaginitis may have induced an immune
response against the PDC-E2 autoantigen contributing
to the loss of immunological tolerance and the induction
of primary biliary cirrhosis [1,4,13]. Thus, lactobacillus
vaccination therapy of recurrent bacterial vaginitis
might be another culprit for development of PBC in
genetically susceptible women.References
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